Gracell Biotechnologies to Participate in Oppenheimer 32nd Annual Healthcare Conference

Rhea-AI Summary

Gracell Biotechnologies (NASDAQ: GRCL) announced its participation in the Oppenheimer 32nd Annual Healthcare Conference from March 15-17, 2022. The management team will present on March 15 from 11:20 AM to 11:50 AM ET and host virtual investor meetings. A webcast of the presentation will be available on the company's website for 90 days post-event. Gracell specializes in developing innovative cell therapies to treat cancer, utilizing technology platforms like FasTCAR and TruUCAR to address challenges in conventional CAR-T therapies.

PALO ALTO, Calif. and SUZHOU, China, March 10, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the Oppenheimer 32^nd Annual Healthcare Conference from March 15^th to 17^th.

The Gracell team is scheduled to have a presentation at 11:20am – 11:50am Eastern Time, Tuesday, March 15^th and will host virtual investor meetings at the conference on March 15^th.

A webcast of the presentation will be available on the "Events and Presentations" page of the Investors section of the Company's website. A replay of the webcast will be available for 90 days following the event. For more information, please visit ir.gracellbio.com.

About Gracell

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR, TruUCAR and SMART CART™ technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.

Media contact
Marvin Tang
marvin.tang@gracellbio.com

Investor contact
Gracie Tong
gracie.tong@gracellbio.com

FAQ

When is Gracell's presentation at the Oppenheimer Healthcare Conference?

Gracell's presentation is scheduled for March 15, 2022, from 11:20 AM to 11:50 AM ET.

What will Gracell discuss at the Oppenheimer Conference?

Gracell will present its innovative approaches to cell therapies for cancer treatment.

Where can I watch Gracell's presentation?

The presentation will be webcast on Gracell's 'Events and Presentations' page and available for 90 days afterward.

What technologies does Gracell use for cancer therapies?

Gracell utilizes FasTCAR, TruUCAR, and SMART CART™ technologies to improve cell therapy effectiveness.

How can I contact Gracell for investor inquiries?

Investor inquiries can be directed to Gracie Tong via email at gracie.tong@gracellbio.com.